Rollins Inc. Stock Slips 4.4%, Underperforms Market
Dow Jones2026/09/15 20:34This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Rollins Inc. slipped 4.4% to $33.77 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.4% to 7,585.73 and Dow Jones Industrial Average falling 0.6% to 52,093.11.
The stock's fall snapped a three-day winning streak.
Rollins Inc. closed 48.9% short of its 52-week high of $66.14, which the company reached on February 11th.
The stock underperformed when compared to some of its peers, as Ecolab Inc. fell 0.1% to $274.60.
Trading volume totaled 6.5 million, compared to the 50-day average of 5.3 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 15, 2026 16:34 ET (20:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
Crypto prices
More
